Amelia Mackenzie is an Associate Scientist in the Contraceptive Technology Innovation Department at FHI 360 where she studies user acceptability of new contraceptive methods in the Department’s development pipeline. She is also a doctoral candidate in the Gillings School of Global Public Health at the University of North Carolina at Chapel Hill. Complementing her work at FHI 360, Mackenzie’s dissertation explores two factors related to contraceptive acceptability: menstrual bleeding side effects and partner opposition to contraception.
Previously, Mackenzie worked at the Bill & Melinda Gates Institute for Population and Reproductive Health on Performance Monitoring and Accountability 2020 (PMA2020), an mHealth project monitoring contraceptive use and access via household and health facility surveys in 10 countries in Africa and Asia. Her experience in the field of reproduction also extends to the laboratory, where her research has examined the origin of various types of poor reproductive outcomes by identifying molecular and mechanical abnormalities in oocytes that develop after ovulation and a treatment for advanced maternal age infertility that is currently being tested in clinical trials.
Mackenzie has a Master of Science degree in Reproductive Biology from the Johns Hopkins Bloomberg School of Public Health.